We are PASSIONATE. CORE VALUES LEADERSHIP BOD & SAB We Are Patient Focused and Outcomes Driven Here at Ardelyx, we are dedicated to improving the lives of patients by developing and commercializing first-in-class targeted therapies that advance patient care. Using our discovery model, Ardelyx scientists have identified new biological mechanisms and pathways that have enabled us to develop a pipeline of drug candidates designed to better manage complications related to kidney and cardiorenal diseases with the goal of improving outcomes for this large population of underserved patients. Tenapanor Our lead candidate, tenapanor, is a first-in-class, targeted, small molecule therapy in development for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. The company believes that, if approved, tenapanor could become a foundational therapy for all patients on dialysis who suffer from hyperphosphatemia, a condition of elevated levels of phosphate in the blood, completely changing the treatment paradigm and making effective and consistent phosphate control possible. OUR SCIENCE Our Pipeline We are also developing earlier-stage candidates that further leverage our discovery capabilities and deep understanding of transport mechanisms, targeting specific pharmacologic pathways. RDX013 is a program focused on developing drug candidates for the treatment of hyperkalemia, a condition resulting from elevated levels of potassium in the blood, and additional pre-clinical projects across other indications are advancing. OUR PIPELINE Ardelyx is publicly traded on the Nasdaq Global Market under the symbol ARDX. Tapping into the best talent on both coasts and everywhere in between, we maintain dual headquarters in the greater San Francisco and Boston biotech communities. Our Commitment to Compliance At Ardelyx, we foster a culture of compliance and hold our employees, contractors, and other representatives acting on our behalf to a high standard of business and professional conduct. Our core values—passionate, fearless, dedicated, inclusive—guide how we treat each other, our customers, and our patients. LEARN MORE Ardelyx Core Values Passionate With integrity and determination, we make a difference for patients. Fearless By challenging convention, we truly innovate. Dedicated Working tirelessly together, we are greater than the sum of our parts. Inclusive With respect, grace and humor, we are family. JOIN OUR TEAM Management Team Mike Raab President & Chief Executive Officer Robert Blanks, MS RAC Chief Regulatory Affairs & Quality Assurance Officer Elizabeth Grammer, Esq. Chief Legal & Administrative Officer David Rosenbaum, PhD Chief Development Officer Jeff Jacobs, PhD Chief Scientific Officer Justin Renz Chief Financial Officer Susan Rodriguez Chief Commercial Officer Laura Williams, MD MPH Chief Medical Officer Sarah O’Brien Chief People Officer Board of Directors David Mott Chairman Geoffrey A. Block, MD Director Mike Raab Director Robert Bazemore Director Onaiza Cadoret-Manier Director Muna Bhanji, R.Ph Director William A. Bertrand, Jr., JD Director Jan M. Lundberg, PhD Director Richard Rodgers Director Scientific Advisory Board Geoffrey A. Block, MD Kevin J. Martin, MB, BCh, BAO Glenn M. Chertow, MD, MPH Sharon M. Moe, MD Stuart M. Sprague, DO Derek Forfang Rory C. Pace, MPH, RD, CSR, FAND Francesca Tentori, MD, MS Kam Kalantar-Zadeh, MD, MPH, PhD Pablo E. Pergola, MD, PhD Our Logo The Ardelyx “A” – Since our founding in 2007, we have been focused on translating our deep understanding of biological mechanisms of ion transport into life-changing medicines. Our stylized “A” visually represents the promise of therapeutics when they interact with specific biological targets. While our logo has evolved over time, we have maintained our unique “A” to recognize our lasting commitment to scientific discovery for the benefit of patients. Bay Area 34175 Ardenwood Boulevard Fremont, CA 94555 Greater Boston 400 Fifth Avenue, Suite 210 Waltham, MA 02451 Phone: 617.675.ARDX (2739) Inquiries: General: info@ardelyx.com Media: media@ardelyx.com Investor: investor@ardelyx.com Business Development: partnering@ardelyx.com © [year] Ardelyx® Terms & Conditions · Privacy Policy Expanded Access · Forward Looking Statements SITE DESIGN BY D&CO We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits, as explained in our Privacy & Cookies Policy. By clicking “Accept”, you consent to the use of ALL the cookies. Accept